International Growth During Pandemic: Dusseldorf’s DxPx Conference Expands Its Scope to the US

DUSSELDORF, Germany – Currently the event industry is facing big challenges due to the corona measures. While some venues and event agencies have already been forced to close doors, other companies are even able to expand despite tougher conditions. One of these companies is the Dusseldorf-based SLS Partnering GmbH, organizing the DxPx Industry & Investor Conference – – every year parallel to MEDICA. The DxPx is Europe’s largest partnering conference for companies in the Diagnostic, Precision Medicine and Life Science Research Tool Industry. With its unique concept, it attracts a global audience of executives and founders. The conference offers startups and growth companies the optimal setting to negotiate with established companies and investors about cooperation and funding.

With strong partners such as one of the leading investment banks Brown Gibbons Lang & Company LLC and the international law firm McDermott Will & Emery LLP, the event expands to the US for the first time. The five-day US partnering conference will take place virtually from July 27th – 31st, 2021 at Chicago time to enable international guests to participate despite travel restrictions. The conference offers discussion forums and a virtual exhibition of well-known partners and innovative companies. In addition, individually planned business meetings can be arranged effectively using the dedicated partnering tool. “As organizers, we’re convinced that innovation and exchange are a perfect way to evolve, especially during and despite of challenging times”, said initiator Dr. Mirko Stange, looking forward to another successful DxPx Conference.

Already last year, SLS Partnering recorded growth for its flagship conference in November. As a reaction to the Corona measures, the DxPx was organized completely digitally for the first time. Over 500 participants from over 30 different countries connected and with more than 1,300 booked meetings, the number has doubled compared to the previous year. The conference was able to convince the industry experts with an attractive program: Interesting panel discussions, a pitch award for startups and contributions from well-known speakers, generated more than 1,600 views on the live stream.

SLS Partnering hopes to hold this year’s Flagship Conference in Dusseldorf again with the recommended hygiene and protective measures from November 16th – 20th, 2021.

About SLS Partnering GmbH

SLS Partnering GmbH is an event and media agency focusing on life sciences and organizes the world’s only international investor partnering conference for players in the fields of diagnostics, precision medicine and research tools – the DxPx Conference. SLS Partnering is taking on the existing challenge of an increasing number of companies seeking capital and ensures a more effective partnering process for both sides. SLS Partnering also offers their additional services in media creation and marketing as life science media and event partner.

Press Contact

Jacqueline Soldan 
SLS Partnering GmbH 

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.


Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.


John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.


Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.


FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.